{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhang Q"],"funding":["Fundamental Research Funds for the Central Universities","Zhejiang Provincial Natural Science Foundation of China","National Natural Science Foundation of China"],"pagination":["50"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12829069"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["Background
Polycystic ovary syndrome (PCOS) is a prevalent reproductive endocrine disorder. The traditional Chinese medicine Bu-Shen-Tian-Jing Formula (BSTJF) has demonstrated efficacy in ameliorating PCOS-related pathologies, however its therapeutic mechanisms remain incompletely understood. This study aimed to investigate the pharmacological mechanisms by which BSTJF improves ovarian microenvironment in PCOS.Methods
BSTJF-containing serum was applied to PCOS granulosa cells (GCs) in vitro for cellular functional assays and transcriptomic sequencing, combined with mass spectrometry-based identification of bioactive components. Network pharmacology and molecular docking were employed to predict multi-target mechanisms of BSTJF against PCOS. In vivo validation utilized an an"],"journal":["Chinese medicine"],"pubmed_title":["Bu-Shen-Tian-Jing Formula alleviates oxidative-inflammatory stress in granulosa cells of polycystic ovary syndrome through AGEs-RAGE/NOX4/NF-κB pathway."],"pmcid":["PMC12829069"],"funding_grant_id":["82405076","Q24H270077","82274564","226-2023-00094"],"pubmed_authors":["Xiang F","Shi B","Ren J","Chen F","Wang F","Qu F","Zhang Q","Ye J","Zhou Z","Zhou J"],"additional_accession":[]},"is_claimable":false,"name":"Bu-Shen-Tian-Jing Formula alleviates oxidative-inflammatory stress in granulosa cells of polycystic ovary syndrome through AGEs-RAGE/NOX4/NF-κB pathway.","description":"Background
Polycystic ovary syndrome (PCOS) is a prevalent reproductive endocrine disorder. The traditional Chinese medicine Bu-Shen-Tian-Jing Formula (BSTJF) has demonstrated efficacy in ameliorating PCOS-related pathologies, however its therapeutic mechanisms remain incompletely understood. This study aimed to investigate the pharmacological mechanisms by which BSTJF improves ovarian microenvironment in PCOS.Methods
BSTJF-containing serum was applied to PCOS granulosa cells (GCs) in vitro for cellular functional assays and transcriptomic sequencing, combined with mass spectrometry-based identification of bioactive components. Network pharmacology and molecular docking were employed to predict multi-target mechanisms of BSTJF against PCOS. In vivo validation utilized an an","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-21T04:48:33.209Z","creation":"2026-06-21T03:07:50.407Z"},"accession":"S-EPMC12829069","cross_references":{"pubmed":["41578404"],"doi":["10.1186/s13020-026-01333-z"]}}